This review highlights emerging therapeutic targets for hypercholesterolemia, including antisense RNAs, microRNAs, and monoclonal antibodies, which hold promise for combating atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Tomkin et al. (2017) conducted a review in Hypercholesterolemia. Investigational therapies (antisense RNAs, microRNAs, human monoclonal antibodies) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: